Clinical trial
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007…
NCT00281528 · Celgene, Industry · Terminated
Key facts
| NCT number | NCT00281528 |
|---|---|
| Title | Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer |
| Official title | A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer. |
| Lead sponsor | Celgene, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | ABI-007 (Abraxane), bevacizumab |
| Enrollment | 208 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Mar 1, 2011 |
| First posted | Jan 25, 2006 |
| Last update posted | Nov 22, 2019 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: